Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / praxis precision medicines to participate in upcomin

PRAX - Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines Inc.

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.

  • Praxis management will participate in a fireside chat at the Needham 23 rd Annual Healthcare Conference , taking place virtually on April 8, 2024 at 8:00a.m EDT. A live webcast of the fireside chat will be available through this link , and also available on the “Investors + Media” section of the company’s website www.praxismedicines.com . A replay of the webcast will be available on Praxis’ website for 90 days following the event.
  • Management will also participate in the Piper Sandler Spring Biopharma Symposium , taking place in Boston, MA on April 16-17, 2024.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .


Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452  Media Contact:Dan FerryLife Science AdvisorsDaniel@lifesciadvisors.com617-430-7576
Stock Information
Company Name: Praxis Precision Medicines Inc.
Stock Symbol: PRAX
Market: NASDAQ
Website: praxismedicines.com
Menu
PRAX PRAX Quote PRAX Short PRAX News PRAX Articles PRAX Message Board
Get PRAX Alerts

News, Short Squeeze, Breakout and More Instantly...